- Home
- CHPT vs CCCC Comparison
CHPT vs CCCC Comparison
Compare CHPT & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHPT
- CCCC
- Stock Information
- Founded
- CHPT 2007
- CCCC 2015
- Country
- CHPT United States
- CCCC United States
- Employees
- CHPT N/A
- CCCC N/A
- Industry
- CHPT Industrial Specialties
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- CHPT Consumer Discretionary
- CCCC Health Care
- Exchange
- CHPT Nasdaq
- CCCC Nasdaq
- Market Cap
- CHPT 340.1M
- CCCC 175.1M
- IPO Year
- CHPT N/A
- CCCC 2020
- Fundamental
- Price
- CHPT $10.77
- CCCC $3.32
- Analyst Decision
- CHPT Hold
- CCCC Strong Buy
- Analyst Count
- CHPT 10
- CCCC 4
- Target Price
- CHPT $19.11
- CCCC $8.50
- AVG Volume (30 Days)
- CHPT 473.6K
- CCCC 1.3M
- Earning Date
- CHPT 09-03-2025
- CCCC 10-30-2025
- Dividend Yield
- CHPT N/A
- CCCC N/A
- EPS Growth
- CHPT N/A
- CCCC N/A
- EPS
- CHPT N/A
- CCCC N/A
- Revenue
- CHPT $397,731,000.00
- CCCC $34,240,000.00
- Revenue This Year
- CHPT N/A
- CCCC N/A
- Revenue Next Year
- CHPT $11.08
- CCCC N/A
- P/E Ratio
- CHPT N/A
- CCCC N/A
- Revenue Growth
- CHPT N/A
- CCCC 16.55
- 52 Week Low
- CHPT $8.55
- CCCC $1.09
- 52 Week High
- CHPT $31.40
- CCCC $7.14
- Technical
- Relative Strength Index (RSI)
- CHPT 48.31
- CCCC 67.30
- Support Level
- CHPT $10.38
- CCCC $3.21
- Resistance Level
- CHPT $11.11
- CCCC $3.65
- Average True Range (ATR)
- CHPT 0.60
- CCCC 0.25
- MACD
- CHPT 0.03
- CCCC 0.07
- Stochastic Oscillator
- CHPT 60.58
- CCCC 75.00
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.